Results 231 to 240 of about 249,811 (339)

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Longitudinal relationships between daily activity and hippocampal atrophy in Japanese dwellers. [PDF]

J Gerontol A Biol Sci Med Sci
Yuki A, Nishita Y, Nakamura A, Kato T, Tange C, Zhang S, Ando F, Shimokata H, Otsuka R.   +8 more
europepmc   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Yhteisöllisyys kantaa seniorityössä

JAMK Journal of Health and Social Studies, 2018
Vesa Vainiomäki, Maarit Heikkilä
doaj  

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

ESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage, Jason N. Dungu, Anthony Dimarco, Brian Li, Samantha Langley, Jonathan Kojo Amoah, Paraic Cliffe, Archana Ganapathy, Peter Watters, Patricia Campbell, Nicola Melarkey, Simon Duckett, Sean Davies, Matthew Dewhurst, Karen Hann, Louise Clayton, Rhys Williams, Victoria Ruszala, Teresa Onwere‐Tan, Fozia Zahir Ahmed, Ibrahim Arosi, Kimberly Gray, Mark C. Petrie, John G.F. Cleland   +23 more
wiley   +1 more source

An autopsy case of bullous retinal detachment and hypopyon in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. [PDF]

Am J Ophthalmol Case Rep
Takenaka M, Ikegami Y, Kamino S, Arai T, Miyakoshi S, Takao H, Yamamoto H, Yoshimoto M, Numaga J.   +8 more
europepmc   +1 more source

Gerontology in the world of health promotion

, 1999
Maurice B. Mittelmark
openalex   +1 more source

A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies

ESC Heart Failure, EarlyView.
The aim of our study was to develop a more accurate staging system for hereditary ATTR patients currently receiving specific treatment. A staging system was created using as criteria: GLS ≤ −11%, NT‐proBNP ≤ 2,000 ng/L, and eGFR ≤ 65 mL/min. We managed to accurately stratify patients into three disease stages, significantly different in terms of ...
Gabriela Neculae, Amira Zaroui, Robert Adam, Mounira Kharoubi, Benoit Funalot, Daniel Coriu, Ruxandra Jurcut, Thibaud Damy   +7 more
wiley   +1 more source

Impaired insulin receptor function alters psychiatric behaviors without affecting circadian rhythms in a mouse model of Alzheimer's disease. [PDF]

Geriatr Gerontol Int
Izuo N, Yokote K, Shimizu T.
europepmc   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

ESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann‐Kathrin Schäfer, Michael J. Koziolek, Manuel Wallbach   +9 more
wiley   +1 more source